https://www.zacks.com/stock/news/2221922/bristol-myers-bmy-tsvt-car-t-cell-therapy-to-face-fda-s-odac?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2221922
Feb 06, 2024 - Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.
zc:8567294693272462537
0
https://www.zacks.com/stock/news/2223559/t-rowe-price-trow-q4-earnings-beat-estimates-aum-rises-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2223559
Feb 08, 2024 - T. Rowe Price's (TROW) Q4 earnings beat estimates on increased net revenues, an improvement in AUM and a decline in expenses. A rise in cash and cash equivalents will help it continue investing.
zc:-6853405466055614972
0
https://www.fool.com/investing/2024/02/12/3-cheap-tech-stocks-to-buy-right-now/?source=iedfolrf0000001
Feb 12, 2024 - IBM, AT&T, and Cisco are all attractive safe haven plays.
0
fool:-8634066573489740201
0
https://www.zacks.com/stock/news/2227782/want-better-returns-don-t-ignore-these-2-consumer-discretionary-stocks-set-to-beat-earnings?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2227782
Feb 19, 2024 - Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
zc:3326214368992771080
0
https://www.zacks.com/commentary/2232353/top-analyst-reports-for-eli-lilly-procter-gamble-morgan-stanley?cid=CS-ZC-FT-research_daily-2232353
Feb 27, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), The Procter & Gamble Company (PG) and Morgan Stanley (MS).
zc:-4727743462274195510
0
https://www.zacks.com/stock/news/2236364/w-t-wti-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2236364
Mar 05, 2024 - While the top- and bottom-line numbers for W&T (WTI) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zc:-7396144779111220938
0
https://www.zacks.com/stock/news/2235902/want-better-returns-don-t-ignore-these-2-consumer-discretionary-stocks-set-to-beat-earnings?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2235902
Mar 05, 2024 - The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
zc:3298378898799320417
0
https://www.zacks.com/stock/news/2236197/earnings-estimates-rising-for-t-rowe-trow-will-it-gain?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_8-2236197
Mar 05, 2024 - T. Rowe (TROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
zc:-4491410189173717542
0
https://seekingalpha.com/article/4678703-poseida-april-2024-data-could-shed-light-on-differentiated-car-t-advancement?source=feed_all_articles
Mar 16, 2024 - Poseida is expected to release results from the phase 1 study using P-BCMA-ALLO1 on April 8th, 2024. Read why PSTX stock is a Buy.
0
sa:-4593629371493091987
0
https://www.zacks.com/stock/news/2242974/5-reasons-to-invest-in-t-rowe-price-trow-stock-right-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2242974
Mar 19, 2024 - T. Rowe Price's (TROW) solid AUM balance, business diversification initiatives, acquisitions and global reach make it an attractive investment option.
zc:4301884081902904745
0